Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Dr. Mojun Zhu is a hematology-oncology fellow at Mayo Clinic in Rochester. She went to Mount Holyoke College and double majored in biology and chemistry. She received her medical degree from Yale University and completed residency training at Yale New Haven Hospital. She will graduate from the fellowship program in 2021 and looks forward to starting a career in academia.
Mandarin Lung Cancer Library - Could Preoperative Immunotherapy Improve Outcomes - Early Stage NSCLC
dbrock
普通话肺癌图书馆-术前免疫疗法能否改善结局-早期NSCLC
Image
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Zhu discusses whether preoperative immunotherapy could improve outcomes in early stage non small cell lung cancer.
*****
Zhu Mojun Zhu博士加入GRACE任客座教授，为普通话社区提供最新信息，以向我们的普通话肺癌视频库提供信息。 在此视频中，朱博士讨论了术前免疫疗法是否可以改善早期非小细胞肺癌的预后。
To join the conversation, visit https://cancergrace.org/forum.
要加入对话，请访问https://cancergrace.org/forum。
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Online Community
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...